Acurx Pharmaceuticals (ACXP) Competitors $0.89 +0.05 (+5.94%) As of 01/3/2025 05:38 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ACXP vs. KRON, GANX, SPRO, VIRI, MURA, DYAI, RPTX, ALVR, ITRM, and ALRNShould you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Kronos Bio (KRON), Gain Therapeutics (GANX), Spero Therapeutics (SPRO), Virios Therapeutics (VIRI), Mural Oncology (MURA), Dyadic International (DYAI), Repare Therapeutics (RPTX), AlloVir (ALVR), Iterum Therapeutics (ITRM), and Aileron Therapeutics (ALRN). These companies are all part of the "pharmaceutical products" industry. Acurx Pharmaceuticals vs. Kronos Bio Gain Therapeutics Spero Therapeutics Virios Therapeutics Mural Oncology Dyadic International Repare Therapeutics AlloVir Iterum Therapeutics Aileron Therapeutics Acurx Pharmaceuticals (NASDAQ:ACXP) and Kronos Bio (NASDAQ:KRON) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, community ranking, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation. Which has more volatility & risk, ACXP or KRON? Acurx Pharmaceuticals has a beta of -1.86, indicating that its stock price is 286% less volatile than the S&P 500. Comparatively, Kronos Bio has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500. Does the MarketBeat Community favor ACXP or KRON? Kronos Bio received 7 more outperform votes than Acurx Pharmaceuticals when rated by MarketBeat users. However, 93.33% of users gave Acurx Pharmaceuticals an outperform vote while only 65.63% of users gave Kronos Bio an outperform vote. CompanyUnderperformOutperformAcurx PharmaceuticalsOutperform Votes1493.33% Underperform Votes16.67%Kronos BioOutperform Votes2165.63% Underperform Votes1134.38% Do institutionals and insiders hold more shares of ACXP or KRON? 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 64.1% of Kronos Bio shares are held by institutional investors. 29.6% of Acurx Pharmaceuticals shares are held by insiders. Comparatively, 24.4% of Kronos Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is ACXP or KRON more profitable? Acurx Pharmaceuticals has a net margin of 0.00% compared to Kronos Bio's net margin of -867.66%. Kronos Bio's return on equity of -64.55% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acurx PharmaceuticalsN/A -392.36% -223.78% Kronos Bio -867.66%-64.55%-48.18% Do analysts rate ACXP or KRON? Acurx Pharmaceuticals currently has a consensus price target of $12.00, suggesting a potential upside of 1,248.47%. Kronos Bio has a consensus price target of $1.63, suggesting a potential upside of 62.50%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Acurx Pharmaceuticals is more favorable than Kronos Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Kronos Bio 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media prefer ACXP or KRON? In the previous week, Acurx Pharmaceuticals had 5 more articles in the media than Kronos Bio. MarketBeat recorded 6 mentions for Acurx Pharmaceuticals and 1 mentions for Kronos Bio. Acurx Pharmaceuticals' average media sentiment score of 1.73 beat Kronos Bio's score of 0.78 indicating that Acurx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acurx Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Kronos Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, ACXP or KRON? Acurx Pharmaceuticals has higher earnings, but lower revenue than Kronos Bio. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Kronos Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcurx PharmaceuticalsN/AN/A-$14.58M-$1.09-0.82Kronos Bio$9.86M6.12-$112.67M-$1.43-0.70 SummaryAcurx Pharmaceuticals beats Kronos Bio on 9 of the 16 factors compared between the two stocks. Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACXP vs. The Competition Export to ExcelMetricAcurx PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.03M$6.62B$5.21B$9.05BDividend YieldN/A2.92%4.99%4.15%P/E Ratio-0.8210.7887.7617.30Price / SalesN/A161.941,150.09121.20Price / CashN/A57.1143.2637.87Price / Book2.625.255.185.18Net Income-$14.58M$153.25M$121.62M$226.86M7 Day Performance-0.46%4.84%3.64%3.12%1 Month Performance15.72%0.52%21.12%4.42%1 Year Performance-77.53%5.93%30.61%21.89% Acurx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACXPAcurx Pharmaceuticals2.6358 of 5 stars$0.89+5.9%$12.00+1,248.5%-78.4%$15.03MN/A-0.823Short Interest ↑Positive NewsKRONKronos Bio2.9068 of 5 stars$0.93-0.7%$1.63+74.2%-10.7%$56.30M$9.86M-0.65100Positive NewsGap DownGANXGain Therapeutics3.5324 of 5 stars$2.06+17.0%$7.25+251.9%-31.2%$54.64M$50,000.00-1.8720Gap UpSPROSpero Therapeutics4.6045 of 5 stars$1.00-2.9%$5.00+400.1%-25.2%$54.51M$89.87M14.2946VIRIVirios Therapeutics0.4867 of 5 stars$2.82+7.6%$3.00+6.4%+370.1%$54.31MN/A-10.445News CoverageGap UpMURAMural Oncology3.453 of 5 stars$3.16-1.9%$16.00+406.3%-37.9%$53.78MN/A-0.35119DYAIDyadic International2.6937 of 5 stars$1.82-7.4%$6.00+230.6%+15.0%$53.70M$3.36M-7.897News CoverageHigh Trading VolumeRPTXRepare Therapeutics2.7614 of 5 stars$1.23-4.7%$7.00+469.1%-80.2%$52.29M$66.52M-0.62180High Trading VolumeALVRAlloVir2.9905 of 5 stars$0.45-2.6%N/A-29.0%$51.44MN/A-0.51110Positive NewsGap DownITRMIterum Therapeutics2.6594 of 5 stars$1.84-3.2%$5.00+171.7%-3.6%$50.63MN/A-0.9210ALRNAileron Therapeutics4.0988 of 5 stars$2.30+3.1%$19.00+726.1%-31.3%$49.83MN/A-0.749Positive News Related Companies and Tools Related Companies Kronos Bio Alternatives Gain Therapeutics Alternatives Spero Therapeutics Alternatives Virios Therapeutics Alternatives Mural Oncology Alternatives Dyadic International Alternatives Repare Therapeutics Alternatives AlloVir Alternatives Iterum Therapeutics Alternatives Aileron Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACXP) was last updated on 1/4/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s next tweet could help pay for your retirementElon Musk says the government is going bankrupt. Seniors are getting crushed by inflation.Brownstone Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.